Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia

Haematologica

Volumn 99, Issue 1, 2014, Pages 8-10

  Della Porta, Matteo G ^a   Picone, Cristina ^a   Tenore, Annamaria ^a   Yokose, Norio ^b   Malcovati, Luca ^a   Cazzola, Mario ^a   Ogata, Kiyoyuki ^c,d  

^a UNIVERSITY OF PAVIA   (Italy)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c Japanese Red Cross Society   (Japan)

^d Endoscopic Center   (Japan)

Author keywords

Flow cytometric score; Immunophenotyping; Low grade MDS; Marrow dysplasia; Prognostic

Indexed keywords

FLOW CYTOMETRIC SCORE; IMMUNOPHENOTYPING; LOW-GRADE MDS; MARROW DYSPLASIA; PROGNOSTIC;

BONE MARROW; BONE MARROW CELLS; HUMANS; IMMUNOPHENOTYPING; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 84892569318     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.097188     Document Type: Article

References (10)

1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
2. van de Loosdrecht AA, Westers TM, Westra AH, Drager AM, van der Velden VH, Ossenkoppele GJ. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood. 2008;111(3):1067-1077.
3. Della Porta MG, Malcovati L, Invernizzi R, Travaglino E, Pascutto C, Maffioli M, et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia. 2006;20(4): 549-555.
4. Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet working group. Leukemia. 2012;26(7):1730-1741.
5. Ogata K, Della Porta MG, Malcovati L, Picone C, Yokose N, Matsuda A, et al. Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica. 2009;94(8):1066-1074.
6. Della Porta MG, Picone C, Pascutto C, Malcovati L, Tamura H, Handa H, et al. Multicenter validation of a reproducible flow cyto-metric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study. Haematologica 2012;97(8):1209-1217.
7. Mathis S, Chapuis N, Debord C, Rouquette A, Radford-Weiss I, Park S, et al. Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes. Leukemia. 2013;27(10):1981-1987.
8. Malcovati L, Della Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23(30):7594-7603.
9. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465.
10. Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control. 1974;19:716-723.